We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

A picture of Gen Li, PhD, MBA

Gen Li, PhD, MBA profile page

Prior to founding Phesi in 2007, Dr. Li was head of productivity for Pfizer Worldwide Clinical Development, a position he assumed following Pfizer’s acquisition of Pharmacia, where Dr. Li delivered the first implementation of productivity measurement for clinical development. While at Pharmacia and Pfizer, he contributed to the Centre for Medicines Research (CMR) International database for pharmaceutical R&D performance. He was also instrumental in creating the KMR productivity mode. Previously, Dr. Li led the creation of the first computer-automated resource management system at Bristol-Myers Squibb. Dr. Li received the prestigious Upjohn Award from Pfizer/Pharmacia. He earned his Ph.D. in Biochemistry from Beijing University and an MBA from the Johnson Graduate School of Management at Cornell University.

Got a Question for Gen Li, PhD, MBA?

Get in touch using the contact form linked here and we’ll get back to you shortly

Published Content
Total: 4
Human face looking at an artificial intelligence face.
Industry Insight

Digital Twins and Trial Arms: Is the Future of Single-Arm Oncology Trials Already Here?

In this opinion piece, Dr. Gen Li discusses how AI and predictive analytics are transforming oncology clinical trials.
Building a Stronger Clinical Trials Industry Post-Pandemic: Modal-Guided Design content piece image
Industry Insight

Building a Stronger Clinical Trials Industry Post-Pandemic: Modal-Guided Design

The focus on COVID-19 has caused many trials to be delayed, canceled or scaled back – meaning that the development of new medicines for patients in other areas has been slowed. At the same time, it has exposed pre-existing flaws in the industry. To recover from the pandemic, the industry must now address these underlying issues.
Closer Relationships Between Sponsors and Regulators Could Transform Clinical Trials content piece image

Closer Relationships Between Sponsors and Regulators Could Transform Clinical Trials

Both pharmaceutical companies and regulators have collaborated closely over the course of the COVID-19 pandemic to develop vaccines, diagnostic tests and other therapies quicker than ever before and have shown us that clinical development can be accelerated. However, there are still several long-standing barriers to progress, when the focus isn’t on a global pandemic, that must now be remedied.
Industry Insight

Planning for 2021: Three Lessons the Clinical Development Sector Can Learn From 2020

The clinical trials industry, like many other global sectors, has been hit hard by the pandemic. One outcome has been the necessary diversion of resources to the development of COVID-19 vaccines and treatments alongside the care of critically ill patients. Impending economic contraction around the world means trials are also taking place against a backdrop of tighter budgets, leaving clinical development on a cliff edge as 2021 approaches.